Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | FNTB | P49356 | 1/20 | 0.42 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12663538 | 0.84 | POLB (0.53) | MAOBPOLBNSD2ABL1PPARG | |
| SCHEMBL371638 | 0.80 | CTSV (0.61) | IMPDH2POLBNSD2ABL1PPARG | |
| SCHEMBL4475229 | 0.80 | CTSV (0.61) | IMPDH2POLBNSD2ABL1PPARG | |
| SCHEMBL1892646 | 0.79 | PRKCQ (0.40) | IMPDH2 | |
| SCHEMBL1891358 | 0.78 | IMPDH2 (0.50) | IMPDH2IDH1 | |
| SCHEMBL5033245 | 0.76 | POLB (0.45) | POLBNSD2ABL1PPARGRIN1 | |
| SCHEMBL1894604 | 0.75 | ALDH1A1 (0.45) | POLB | |
| SCHEMBL31253965 | 0.75 | NSD2 (0.61) | IMPDH2MAOBPOLBNSD2ABL1 | |
| SCHEMBL16112035 | 0.75 | NSD2 (0.61) | IMPDH2MAOBPOLBNSD2ABL1 | |
| SCHEMBL1891045 | 0.74 | MDH2 (0.49) | MAOBPOLBNSD2ABL1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10800741-B2 | Quinoline compound, preparation method and medical use therefor | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2020-10-13 | — | — | US | disclosed |
| US-10800741-B2 | Quinoline compound, preparation method and medical use therefor | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2020-10-13 | — | — | US | disclosed |
| EP-0929526-B1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ASTRAZENECA AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| US-6809097-B1 | ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY | ZENECA LIMITED (GB) | 2004-10-26 | — | — | US | disclosed |
| EP-0929526-A1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ZENECA LIMITED (GB) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998013350-A1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ZENECA LIMITED (GB) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800741-B2 | Quinoline compound, preparation method and medical use therefor | WEE2, WEE1, HASPIN | IMPDH2 1125/4885MAOB 2364/4885XDH 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.